 | • レポートコード：TPM-NV131 • 出版社/出版日：Transparency Market Research / 2019年11月8日 • レポート形態：英文、PDF、195ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、IBD（潰瘍性大腸炎およびクローン病）治療の世界市場について調べ、IBD（潰瘍性大腸炎およびクローン病）治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、薬物クラス別（TNF阻害剤、アミノサリチル酸塩、インテグリン拮抗薬、およびコルチコステロイド）分析、疾患別（潰瘍性大腸炎＆クローン病）分析、流通チャンネル別（病院薬局、小売薬局、オンライン薬局）分析、関連企業情報などをまとめました。 ・IBD（潰瘍性大腸炎およびクローン病）治療の市場概要 ・IBD（潰瘍性大腸炎およびクローン病）治療の市場動向 ・IBD（潰瘍性大腸炎およびクローン病）治療の世界市場規模・予測 ・IBD（潰瘍性大腸炎およびクローン病）治療市場：薬物クラス別（TNF阻害剤、アミノサリチル酸塩、インテグリン拮抗薬、およびコルチコステロイド） ・IBD（潰瘍性大腸炎およびクローン病）治療市場：疾患別（潰瘍性大腸炎＆クローン病） ・IBD（潰瘍性大腸炎およびクローン病）治療市場：疾患別（潰瘍性大腸炎＆クローン病） ・地域別分析（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争環境・関連企業分析 |
Several ongoing drug development projects signify increased reliability of patients on inflammatory bowel disease (IBD) treatment. Based on disease indication, a study published by Transparency Market Research (TMR) reported that, therapeutics for ulcerative colitis are projected to have a relatively wider patient pool than Crohn’s disease, and that their collective sales will reflect on the healthy growth of the IBD (ulcerative colitis and Crohn’s disease) treatment market.
Numerous non-profit institutions along with the governments of various regions are found taking initiatives to educate individuals regarding IBD through campaigns and workshops, which is progressively increasing the patient base for the IBD (ulcerative colitis and Crohn’s disease) treatment market. Besides the informative approach of public organizations, privately-held pharmaceutical companies sense the lucrative landscape that the IBD treatment market is, and are making profits by addressing unmet treatment needs through the development of effective therapeutics.
In the future, the recent development of anti-adhesion molecules will serve as an open ground for market players to introduce new formulations, and target patients who fail to respond to traditional therapeutics. That being said, considering the underlying opportunities that market players are likely to explore to remain as patient-centric as possible, the TMR study projects an above-average growth of the IBD (ulcerative colitis and Crohn’s disease) treatment market, at an estimated CAGR of ~6% during 2019-2027
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market
4. Market Overview
4.1. Introduction
4.2. Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Value (US$ Mn) Forecast, 2017–2027
5. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market, Key Insights
5.1. Clinical Trial Pipeline Analysis: IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market
5.2. Disease Prevalence: IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market
5.3. Major Deals & Strategic Alliances Analysis: IBD (Ulcerative Colitis & Crohn’s Disease) Treatment Market
6. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast, by Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027
6.3.1. TNF Inhibitors
6.3.2. Aminosalicylates
6.3.3. Integrin Antagonists
6.3.4. Corticosteroids
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecasts, by Disease Indication
7.1. Key Findings
7.2. Introduction
7.3. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027
7.3.1. Ulcerative Colitis
7.3.2. Crohn’s Disease
7.4. Market Attractiveness Analysis, by Disease Indication
8. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecasts, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market Value (US$ Mn) Forecast by Distribution Channel, 2019–2027
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Market Value (US$ Mn) Forecast, by Region, 2019–2027
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Market Attractiveness Analysis, by Region
10. North America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast
10.1. Key Findings
10.2. Market Value (US$ Mn) Forecast, by Country, 2019–2027
10.2.1. U.S.
10.2.2. Canada
10.3. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027
10.3.1. TNF Inhibitors
10.3.2. Aminosalicylates
10.3.3. Integrin Antagonists
10.3.4. Corticosteroids
10.3.5. Others
10.4. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027
10.4.1. Ulcerative Colitis
10.4.2. Crohn’s Disease
10.5. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Attractiveness Analysis
10.6.1. By Country
10.6.2. By Drug Class
10.6.3. By Disease Indication
10.6.4. By Distribution Channel
11. Europe IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast
11.1. Key Findings
11.2. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027
11.2.1. Germany
11.2.2. U.K.
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027
11.3.1. TNF Inhibitors
11.3.2. Aminosalicylates
11.3.3. Integrin Antagonists
11.3.4. Corticosteroids
11.3.5. Others
11.4. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027
11.4.1. Ulcerative Colitis
11.4.2. Crohn’s Disease
11.5. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Attractiveness Analysis
11.6.1. By Country/Sub-region
11.6.2. By Drug Class
11.6.3. By Disease Indication
11.6.4. By Distribution Channel
12. Asia Pacific IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast
12.1. Key Findings / Developments
12.2. Market Overview
12.3. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027
12.4.1. TNF Inhibitors
12.4.2. Aminosalicylates
12.4.3. Integrin Antagonists
12.4.4. Corticosteroids
12.4.5. Others
12.5. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027
12.5.1. Ulcerative Colitis
12.5.2. Crohn’s Disease
12.6. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027
12.6.1. Hospital Pharmacies
12.6.2. Retail Pharmacies
12.6.3. Online Pharmacies
12.7. Market Attractiveness Analysis
12.7.1. By Country/Sub-region
12.7.2. By Drug Class
12.7.3. By Disease Indication
12.7.4. By Distribution Channel
13. Latin America IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027
13.4.1. TNF Inhibitors
13.4.2. Aminosalicylates
13.4.3. Integrin Antagonists
13.4.4. Corticosteroids
13.4.5. Others
13.5. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027
13.5.1. Ulcerative Colitis
13.5.2. Crohn’s Disease
13.6. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027
13.6.1. Hospital Pharmacies
13.6.2. Retail Pharmacies
13.6.3. Online Pharmacies
13.7. Market Attractiveness Analysis
13.7.1. By Country/Sub-region
13.7.2. By Drug Class
13.7.3. By Disease Indication
13.7.4. By Distribution Channel
14. Middle East and Africa IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Market Value (US$ Mn) Forecast, by Country/Sub-region, 2019–2027
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East and Africa
14.4. Market Value (US$ Mn) Forecast, by Drug Class, 2019–2027
14.4.1. TNF Inhibitors
14.4.2. Aminosalicylates
14.4.3. Integrin Antagonists
14.4.4. Corticosteroids
14.4.5. Others
14.5. Market Value (US$ Mn) Forecast, by Disease Indication, 2019–2027
14.5.1. Ulcerative Colitis
14.5.2. Crohn’s Disease
14.6. Market Value (US$ Mn) Forecast, by Distribution Channel, 2019–2027
14.6.1. Hospital Pharmacies
14.6.2. Retail Pharmacies
14.6.3. Online Pharmacies
14.7. Market Attractiveness Analysis
14.7.1. By Country/Sub-region
14.7.2. By Drug Class
14.7.3. By Disease Indication
14.7.4. By Distribution Channel
15. Competition Landscape
15.1. Global IBD (Ulcerative Colitis and Crohn’s Disease) Treatment Market Share, by Company, 2018
15.2. Market Player – Competition Matrix (By Tier and Size of companies)
15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.3.1. Pfizer, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Strategic Overview
15.3.2. Janssen Biotech, Inc. (Johnson & Johnson)
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Valeant Pharmaceuticals International, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Allergan plc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Takeda Pharmaceutical Company Limited.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. AbbVie, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Novartis AG
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. UCB Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Biogen Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview